
<!DOCTYPE html>
<html>
<head>
<title>12_1_MASTER_ALEXION_P03_T05_S02</title>
<meta name="viewport" content="user-scalable=no, width=device-width, initial-scale=1.0, maximum-scale=1.0"/>
<meta name="apple-mobile-web-app-capable" content="yes" />
<meta name="format-detection" content="telephone=no" />


<link href="../global/css/font.css" type="text/css" rel="stylesheet">
<link href="../global/css/global.css" type="text/css" rel="stylesheet">
<link href="css/main.css" type="text/css" rel="stylesheet">
<meta http-equiv="Content-Type" content="text/html; charset=utf-8">
</head>
<body>
<!--menu top-->
<div id="container">
<div class="logo"></div>
<!--end elements-->
<div id="main_container" class="bg_blue_full">
  <div class="people"></div>
  <div class="btn_reload"></div>
  <div class="text_top">
    <div class="title_top Helvetica_Round_Bold">
      <i18n id="v2_txt1">With VIMOVO, patients 
        experience proven pain relief...</i18n>
    </div>
    <div class="percent Helvetica_Round_Bold">
      <i18n id="v2_txt2">FlowA</i18n>
    </div>
    <div class="percent_2 Helvetica_Round_Bold">
      <i18n id="v2_txt2_2">FlowA</i18n>
    </div>
    <div class="percent_right HelveticaLTStd_Roman">
      <i18n id="v2_txt3"><span class="Helvetica_Round_Bold font_bold">overall improvement in OA</span><br>
        as measured by Patient Global
        Assessment Scores—Visual Analog
        Scale vs placebo at 12 weeks.<sup>1</sup></i18n>
    </div>
  </div>
  <div class="text_bottom">
    <div class="title_bot Helvetica_Round_Bold">
      <i18n id="v2_txt4">while getting help improving
        upper-GI<sup>§</sup> tolerability.</i18n>
    </div>
    <div class="percent_bot Helvetica_Round_Bold">
      <i18n id="v2_txt5">FlowB</i18n>
    </div>
    <div class="percent_bot2 Helvetica_Round_Bold">
      <i18n id="v2_txt5_2">FlowB</i18n>
    </div>
    <div class="percent_right_bot HelveticaLTStd_Roman">
      <i18n id="v2_txt6"><span class="Helvetica_Round_Bold font_bold">fewer discontinuations</span><br>
        due to predefined, NSAID-related,
        upper-GI issues (including duodenal
        ulcers) vs EC naproxen monotherapy.<sup>2,3</sup></i18n>
    </div>
  </div>
  <div class="page"></div>
  <div class="claim">
    <i18n id="v3_claim004">VIMOVO: The balanced approach to OA<sup>‡</sup> pain relief.<sup>1</sup></i18n>
  </div>
</div>
<!--End #main_container -->
<div class="ref_wrapper" id="ref_all"></div>
<div id="scroll-wrapper" class="scroll_ref">
  <div id="scroller">
    <h1 class="brown Helvetica_Round_Bold">
      <i18n id="v2_v1_S007_ref">References:</i18n>
    </h1>
    <div class="ref HelveticaLTStd_Roman"> <span class="ref_number">1.</span>
      <i18n id="v2_v1_S007_ref_txt0">Hochberg, MC, et al. <span class="HelveticaNeueLTStd_it">Curr Med Res Opin</span> 2011; 27: 1243-53.</i18n>
    </div>
    <div class="ref HelveticaLTStd_Roman"> <span class="ref_number">2.</span>
      <i18n id="v2_v1_S007_ref_txt1">Adapted from Goldstein, JL, et al. <span class="HelveticaNeueLTStd_it">Aliment Pharmacol Ther</span> 2010; 32: 401-413. </i18n>
    </div>
    <div class="ref HelveticaLTStd_Roman"> <span class="ref_number">3.</span>
      <i18n id="v2_v1_S007_ref_txt100">Predefined upper-GI adverse events include: abdominal 
        discomfort, abdominal pain, abdominal tenderness, duodenal hemorrhage,
        duodenal scarring, DU hemorrhage, duodenitis, dyspepsia, epigastric discomfort, erosive esophagitis, erosive gastritis, esophageal discomfort,
        esophageal disorder, esophageal hemorrhage, esophageal stenosis, esophageal ulcer, esophageal varices, esophagitis, gastric hemorrhage, gastric mucosal lesion, gastritis, GERD, gastro-esophagitis, GI erosion, GI hemorrhage, GI mucosal disorder, hemorrhagic duodenitis, hemorrhagic gastritis, hyperchloridia, nausea, reflux esophagitis, stomach discomfort, upper abdominal pain, vomiting (NSAID, nonsteroidal anti-inflammatory drug; AE, adverse event; DU, duodenal ulcer; GERD, gastro-esophageal reflux disease). </i18n>
    </div>
    <div class="ref HelveticaLTStd_Roman"> <span class="ref_number">†</span>
      <i18n id="v2_v1_S007_ref_txt5">Helping to improve upper-GI tolerability is evidenced by fewer upper-GI ulcers, fewer discontinuations due to upper-GI AEs including duodenal ulcers,
        and less abdominal discomfort over a 6-month period as measured by dyspepsia symptoms versus EC naproxen. </i18n>
    </div>
    <!--end Ref-->
    
    
    <div class="ref HelveticaLTStd_Roman"> <span class="ref_number">‡</span>
      <i18n id="v2_v1_S007_ref_txt7"> Osteoarthritis </i18n>
    </div>
    <div class="ref HelveticaLTStd_Roman"> <span class="ref_number">§</span>
      <i18n id="v2_v1_S007_ref_txt8"> Gastrointestinal </i18n>
    </div>
  </div>
  <div class="close"><span class="right"></span></div>
  <div class="arrow_ref"></div>
</div>

<!--End area for ref-->

<div class="info_wrapper" id="info_all"></div>
<div id="scroll-wrapper" class="scroll_info">
  <div id="scroller">
    <h1 class="grey Helvetica_Round_Bold">
      <i18n id="v10_S007_ref">VIMOVO must be swallowed whole with water, and 
        not split, chewed, or crushed, and it should be taken 
        at least 30 minutes before meals.<br />
        <br />
        <span class="HelveticaLTStd_Roman">Special warnings and precautions:</span></i18n>
    </h1>
    <div class="ref HelveticaLTStd_Roman"> <span class="ref_number">&bull;</span>
      <i18n id="info1">The use of VIMOVO with other concomitant NSAIDs 
        should be avoided.</i18n>
    </div>
    <!--end info-->
    
    <div class="ref HelveticaLTStd_Roman"> <span class="ref_number">&bull;</span>
      <i18n id="info2">VIMOVO must not be used concomitantly with 
        atazanavir and nelfinavir.</i18n>
    </div>
    <!--end info-->
    
    <div class="ref HelveticaLTStd_Roman"> <span class="ref_number">&bull;</span>
      <i18n id="info3">Clinical trial and epidemiological data suggest that use 
        of coxibs and some NSAIDs may be associated with a 
        small increased risk of arterial thrombotic events (for 
        example myocardial infarction or stroke).
        Although data suggests that the use of naproxen     
        (1000mg daily) may be associated with a lower risk, 
        some risk cannot be excluded.</i18n>
    </div>
    <!--end info-->
    <div class="ref HelveticaLTStd_Roman"> <span class="ref_number">&bull;</span>
      <i18n id="info4">Prior to prescribing VIMOVO, a thorough review of the 
        benefit/risk profile of VIMOVO should be undertaken, 
        including an assessment of potential drug interactions. </i18n>
    </div>
    <!--end info-->
    <div class="ref HelveticaLTStd_Roman"> <span class="ref_number">&bull;</span>
      <i18n id="info5">Patients on long-term treatment (over one year) should 
        be kept under regular surveillance. </i18n>
    </div>
    <!--end info-->
    <div class="ref HelveticaLTStd_Roman"> <span class="ref_number">&bull;</span>
      <i18n id="info6">Please refer to the SmPC for a comprehensive review 
        of all reported adverse events, contraindications, 
        interactions, warnings, and precautions. </i18n>
    </div>
    <!--end info--> 
    
    <!--end info--> 
  </div>
  <div class="close"><span class="right"></span></div>
  <div class="arrow_info"></div>
</div>
</div>

</body>
	<script type="text/javascript" src="../global/js/config.js"></script>
    <script type='text/javascript' src='../framework/steal/steal.production.js?../framework,development'></script>
	
	<script src="resource:js/SystemBridge.js"></script>
	<script type="text/javascript" src="../global/js/havie.js"></script>
    <script type="text/javascript" src="../global/js/global.js"></script>
    <script type="text/javascript" src="../global/js/ref.js"></script>
    <script type="text/javascript" src="javascript/main.js"></script>	
</html>